Clinical study on preventive treatment of postpartum hemorrhage with carboprost tromethamine combined with oxytocin and misoprostol

To study the clinical effect of carboprost tromethamine combined with oxytocin and misoprostol in the preventive treatment of postpartum hemorrhage. 94 cases of postpartum hemorrhage patients from October, 2022 to October, 2023 were divided into the reference group (treated with oxytocin and misoprostol) and the observation group (treated with carboprost tromethamine, oxytocin and misoprostol) and the treatment situation was analyzed. Compared with the reference group, the stress and serum indexes in the observation group were significantly decreased. Except oxygen saturation, the postpartum hemorrhage and hemostasis time in the observation group were significantly lower than those in the reference group and the hemoglobin content was relatively high. After treatment, the improvement of coagulation function in the observation group was better than that in the reference group. The incidence of complications was 21.28% in the reference group and 4.26% in the observation group, the difference was statistically significant (P < 0.05). In the preventive treatment of postpartum hemorrhage, triple medication is more effective, which can improve patients' stress response and serum indexes, reduce the amount of bleeding and improve patients' coagulation function. At the same time, it is also very beneficial to control complications and has high safety.